Literature DB >> 3917490

Desipramine binding: relationship to central and sympathetic noradrenergic activity.

A C Swann, R Duman, L Hewitt.   

Abstract

We examined the effects of treatments affecting norepinephrine release on the number of norepinephrine reuptake recognition sites as reflected by desipramine binding. To do this, we used manipulations having similar presynaptic but contrasting postsynaptic effects. Presynaptic inhibition by 6-hydroxydopamine lesion or by clonidine, and postsynaptic receptor stimulation by isoproterenol, reduced desipramine binding. Presynaptic stimulation by d-amphetamine and postsynaptic receptor blockade by prazosin increased desipramine binding. Similar effects and binding properties were seen in cerebral cortex, heart, and soleus muscle. After unilateral noradrenergic lesions, reduction in desipramine binding correlated with reduction in norepinephrine uptake. These results show that norepinephrine reuptake appears to be regulated by transmitter release regardless of effects on postsynaptic transmission, and that this regulation is analogous in the central and sympathetic nervous systems.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3917490     DOI: 10.1111/j.1471-4159.1985.tb05455.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  3 in total

1.  Thyroid hormone and norepinephrine: effects on alpha-2, beta, and reuptake sites in cerebral cortex and heart.

Authors:  A C Swann
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

2.  Release of neuropeptide Y (NPY) induced by tyramine in the isolated vas deferens of rat.

Authors:  J T Cheng; C L Shen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-03       Impact factor: 3.000

Review 3.  Noradrenergic and serotonergic mechanisms in the neurobiology of posttraumatic stress disorder and resilience.

Authors:  John H Krystal; Alexander Neumeister
Journal:  Brain Res       Date:  2009-03-28       Impact factor: 3.252

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.